GGrantIndex
Sort

64,565 grants matching drug discovery

Plasma-Generated Hydroxyl Radicals for Analysis of Three-Dimensional Structures in Protein Therapeutics

$1,037,792
Faraz Choudhury · Immuto Scientific, Inc. · R44 · FY2022 · GM

Reading mitochondrial apoptotic signaling to identify active cancer therapeutics

$1,037,388
Anthony G Letai · Dana-Farber Cancer Inst · R35 · FY2021 · CA

Functional Genomics Laboratory (FGL)

$1,037,104
Ken Cheng · National Center For Advancing Translational Sciences · ZIC · FY2025 · TR

Metabolic Discrimination of Unknown Bacterial Pathogens

$1,036,884
John Peter Wikswo · Vanderbilt University · U01 · FY2007 · AI

Molecular Targets Phase III CoBRE

$1,036,424
Donald M Miller · University Of Louisville · P30 · FY2017 · GM

Structure and Function of Neurotransmitter Transporters

$1,036,387
Harel Weinstein · Weill Medical Coll Of Cornell Univ · P01 · FY2008 · DA

Novel small-molecule therapies for CF

$1,036,332
Alan S Verkman · University Of California, San Francisco · P30 · FY2009 · DK

Next-generation 5-nitroimidazoles against giardiasis

$1,036,268
Lars Eckmann · University Of California, San Diego · U01 · FY2011 · AI

Selection of a lead LPAR1 antagonist for treatment of diabetic neuropathy

$1,035,811
Graham Beaton · Epigen Biosciences, Inc. · R44 · FY2021 · DK

Chemistry Core

$1,035,799
Timothy S Bugni · University Of Wisconsin-Madison · U19 · FY2023 · AI

Novel small-molecule therapies for CF

$1,035,766
Alan S Verkman · University Of California, San Francisco · P30 · FY2008 · DK

Identifying novel anti-infectives by high through-put screening in whole animals

$1,035,268
Frederick M Ausubel · Massachusetts General Hospital · R01 · FY2012 · AI

Comprehensive Cancer Center Program at Fox Chase

$1,035,145
Jonathan D. Chernoff · Research Inst Of Fox Chase Can Ctr · P30 · FY2021 · CA

A 3D vascularized islet biomimetic to model type 1 diabetes

$1,035,118
Maike Sander · University Of California, San Diego · UG3 · FY2020 · DK

Nanodiamond Quantum Sensors for Free Radical Detection

$1,034,967
Marco Torelli · Adamas Nanotechnologies, Inc. · R44 · FY2024 · TR

A multidisciplinary approach to elucidating gene function in a model Gram-positiv

$1,034,875
David Z Rudner · Harvard Medical School · RC2 · FY2010 · GM

Discovery of PSD95 protein-protein interaction inhibitors as novel non-opioid analgesics

$1,034,659
Stephanie K Florio · Anagin · U44 · FY2023 · NS

Molecular Studies of Malformations

$1,034,538
Leslie Biesecker · National Human Genome Research Institute · ZIA · FY2015 · HG

Tri-Institutional Tuberculosis Research Advancement Center (TRAC)

$1,034,397
Daniel W Fitzgerald · Weill Medical Coll Of Cornell Univ · P30 · FY2022 · AI

Development and Testing of New Computational Methods for Ligand Discovery and Mechanism

$1,034,213
Brian K. Shoichet · University Of California, San Francisco · R35 · FY2021 · GM

Development and Testing of New Computational Methods for Ligand Discovery and Mechanism

$1,034,213
Brian K. Shoichet · University Of California, San Francisco · R35 · FY2020 · GM

The Cancer Target Discovery and Development Network at UCSF

$1,034,211
Michael T McManus · University Of California, San Francisco · U01 · FY2017 · CA

CONUS PEPTIDES AND THEIR RECEPTOR TARGETS

$1,034,205
University Of Utah · P01 · FY2002 · GM

Genomic Medicine Implementation: The Personalized Medicine Program

$1,034,134
Julie A. Johnson · University Of Florida · U01 · FY2016 · HG

Development of novel proteins synthesis inhibitors for MDR tuberculosis

$1,034,057
Richard Edward Lee · St. Jude Children'S Research Hospital · R01 · FY2010 · AI